

PRODUCT INFORMATION

Common Name	OMP-313M32
Conjugate	Unconjugated
Synonyms	TIGIT;SIG9;STM3
Applications	ELISA; Flow Cyt
Endotoxin	Less than 1.0 EU/ μ g by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1 - kappa
Reactivity	Human
Target	TIGIT
Uniprot ID	Q495A1
Description	Anti-TIGIT (etigilimab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μ m) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-TIGIT (etigilimab biosimilar) mAb ELISA

0.2 μg of TIGIT, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 $\mu\text{g}/\text{ml}$ (100 $\mu\text{l}/\text{well}$) Human TIGIT, His tagged protein ([getskuurl sku="PME100506"]) can bind Anti-TIGIT Neutralizing antibody in a linear range of 0.13-16.0 ng/ml.

Anti-TIGIT (etigilimab biosimilar) mAb ELISA

0.2 μg of TIGIT, mFc Tagged protein per well




Figure 2. ELISA plate pre-coated by 2 $\mu\text{g}/\text{ml}$ (100 $\mu\text{l}/\text{well}$) Human TIGIT, mFc tagged protein ([getskuurl sku="PME100505"]) can bind Anti-TIGIT Neutralizing antibody in a linear range of 0.13-16.0 ng/ml.






Figure 3. HEK293 cell line transfected with irrelevant protein (**B**) and human TIGIT protein (**A**) were surface stained with anti-TIGIT neutralizing antibody 1 μ g/ml (etigilimab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

